

BOX PATENT
Attorney Docket No. AR218-X

#13
12/9/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gregory S. HAMILTON et al.

Examiner: Celia Chang

Serial No: 09/204,236

Group: 1612

Filed: December 3, 1998

For: **N-LINKED SULFONAMIDES OF HETEROCYCLIC CARBOXYLIC ACIDS OR
CARBOXYLIC ACID ISOSTERES**

LETTER TO THE EXAMINER
REGARDING INFORMATION DISCLOSURE STATEMENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants herein provide a brief description of material described in each reference cited in the Information Disclosure Statement, filed July 15, 1999; Supplemental Information Disclosure Statement, filed July 14, 1999; Fourth Supplemental Information Disclosure Statement filed October 8, 1999; and Fifth Supplemental Information Disclosure Statement filed October 21, 1999. A brief description of the material described in each reference cited in the Second Supplemental Information Disclosure Statement, filed October 8, 1999 and the Third Supplemental Information Disclosure Statement, filed October 8, 1999, was provided therewith. This outline is provided for the convenience of the Examiner and to advance the prosecution of the present application before the United States Patent and Trademark Office.

The Examiner's attention is drawn to the following IDS references containing biological information that the Examiner may

find relevant for reviewing the subject matter of the present invention. The identification letters shown below (**AD**, **AE**, etc.) refer to the reference line numbers cited in the respective Information Disclosure Statements.

Nerves- growth of; regeneration; degeneration:

Information Disclosure Statement:

AA, **AD**, and **AE**.

First Supplemental Information Disclosure Statement:

AA, **AB**, **AE**, **AF**, **AH**, **AO**, **BD**, **BF**, **BG**, **BH**, and **BJ**.

Fourth Supplemental Information Disclosure Statement:

AA, **AB**, **AC**, **AD**, **AE**, **AF**, **AH**, **AI**, **AJ**, **AK**, **AL**, **AM**, **AO**, **AP**,
BI, **CA**, **CB**, **CC**, **CD**, **CE**, **CF**, **CG**, **CH**, **DA**, **DB**, **DC**, **DD**, **DE**,
DF, **DG**, **DH**, **DI**, **DJ**, and **DK**.

Fifth Supplemental Information Disclosure Statement:

AA, **AB**, **AC**, **AD**, **AE**, **AF**, **AG**, **AH**, **AI**, **AJ**, **AK**, **AL**, **AT**, and
AX.

Alzheimer's disease:

Information Disclosure Statement:

AA, **AC**, **AD**, and **AE**.

First Supplemental Information Disclosure Statement:

AA, **AB**, **AE**, **AH**, **AN**, **AO**, **BB**, **BD**, **BF**, **BG**, and **BH**.

Fourth Supplemental Information Disclosure Statement:

AA, **AB**, **AD**, **AE**, **AF**, **AH**, **AI**, **AJ**, **AK**, **AL**, **AM**, **AO**, **AP**, **AU**,
BI, **CC**, **CH**, **DA**, and **DJ**.

Fifth Supplemental Information Disclosure Statement:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AO, AT, AV, and AX.

Parkinson's disease:

Information Disclosure Statement:

AA and AD.

First Supplemental Information Disclosure Statement:

AA, AB, AE, AH, AO, BD, and BG.

Fourth Supplemental Information Disclosure Statement:

AA, AB, AD, AE, AF, AH, AI, AJ, AK, AL, AM, AO, AP, CH, DA, and DI.

Fifth Supplemental Information Disclosure Statement:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AT, and AX.

Amyotrophic lateral sclerosis:

Information Disclosure Statement:

AA and AD.

First Supplemental Information Disclosure Statement:

AA, AB, AE, AG, AH, AM, AN, BE, BG, and BI.

Fourth Supplemental Information Disclosure Statement:

AA, AB, AD, AE, AF, AH, AI, AJ, AK, AL, AM, AP, BE, BF, and BG.

Fifth Supplemental Information Disclosure Statement:

AA, AB, AC, AD, AE, AF, AH, AI, AJ, AK, AL, AN, AT, and AV.

Cerebral ischemia:

First Supplemental Information Disclosure Statement:

AB, AC, BB, and BK.

Fourth Supplemental Information Disclosure Statement:

AA, AB, AF, AH, AI, AJ, AL, BC, BI, CA, and DE.

Fifth Supplemental Information Disclosure Statement:

AL and AT.

Degenerative disorders of nervous system; CNS disorders:

Information Disclosure Statement:

AA and AD.

First Supplemental Information Disclosure Statement:

AA, AE, AH, AL, AO, BB, BD, BF, and BH.

Fourth Supplemental Information Disclosure Statement:

**AD, AE, AF, AK, AM, BI, CD, CH, DF, DI, DJ, and
DK.**

Fifth Supplemental Information Disclosure Statement:

AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AM, and AU.

Memory or Dementia:

First Supplemental Information Disclosure Statement:

BB, BC, BF, and BH.

Fourth Supplemental Information Disclosure Statement:

AD and AE.

Fifth Supplemental Information Disclosure Statement:

AO, AV, and BC.

Eye or vision, or similar disorders:

Information Disclosure Statement:

AC and **AE**.

First Supplemental Information Disclosure Statement:

AA, AB, AD, AE, AG, AH, AI, AJ, AM, AN, AO, BE, BI, BJ,
and **BK**.

Fourth Supplemental Information Disclosure Statement:

AZ, BC, BE, BF, BG, BQ, BR, and BS.

Fifth Supplemental Information Disclosure Statement:

AN, AR, and AS.

Hair Growth or Alopecia:

Information Disclosure Statement:

AB, AE, and AF.

First Supplemental Information Disclosure Statement:

AC, AD and BA.

Fourth Supplemental Information Disclosure Statement:

AC, AF, AG, AQ, AT, AU, AV, AY, BA, BB, BH, BJ, BK, BL,
BM, BN, BO, CJ, CK, and DL.

The following references disclose chemical structures that the Examiner may find relevant for reviewing the subject matter of the present invention.

Information Disclosure Statement:

AB, AC, AF, and AG.

First Supplemental Information Disclosure Statement:

AA, AB, AK, CA, CB, CC, CD, CE, CF, and DA.

Fourth Supplemental Information Disclosure Statement:

AC, AN, AR, AS, AW, AX, AZ, BC, BD, BP, BQ, BT, and CI.

Fifth Supplemental Information Disclosure Statement:


AB, AP, AQ, AS, AW, AX, BA, and BB.

Applicants have taken great care to ensure that the claims of the present invention are patentable over all cited references, but welcome and appreciate the Examiner's consideration of the same.

Please contact the undersigned attorney by telephone should there be any questions or comments.

Respectfully submitted,
NATH & ASSOCIATES

Date: Dec. 30, 1999



Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669

NATH & ASSOCIATES
1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005
(202) 775-8383
GMN:TLJ:JBG:\roadmap



SP/1612

PATENT BOX

Attorney Docket No. AR218-X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Gregory S. HAMILTON et al.

Group Art Unit: 1612

Serial No. 09/204,236

Examiner: Celia Chang

Filed: December 3, 1998

For: **N-LINKED SULFONAMIDES OF HETEROCYCLIC CARBOXYLIC ACIDS OR
CARBOXYLIC ACID ISOSTERES**

TRANSMITTAL LETTER

RECEIVED

JAN 03 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal Letter; and
- 2) Letter to the Examiner.

If extensions of time under 37 CFR § 1.136 other than those provided herewith are required to allow consideration of papers accompanying this Petition, then such extensions of time are hereby petitioned. The Commissioner is specifically authorized to charge fee deficiency under 37 CFR §§ 1.16 or 1.17, or credit any overpayment, to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES

Date: Dec. 30, 1999 By: Todd L. Juneau
Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669

NATH & ASSOCIATES

1030 Fifteenth Street N.W.
Sixth Floor
Washington, D.C. 20005-1503
TEL: (202) 775-8383
FAX: (202) 775-8396